The tariff classification and country of origin of Formoterol Soln Neb (Formoterol Fumarate Inhalation Solution)
No revocation or modification of this ruling appears in the Customs Bulletin issues read here (Nov 6, 2024 through Nov 18, 2026), where CBP publishes most such actions. That is not confirmation that the ruling is still in effect. Confirm its status with CBP before relying on it (ruling on CBP CROSS).
Key passages, quoted from the ruling
- In this case, we find the mixing of the active ingredient, Formoterol Fumarate Dihydrate (made in Italy) with the inactive ingredients into the final Formoterol Fumarate Inhalation Solution in dosage form in India does not result in a substantial transformation and the country of origin will be Italy.
Ruling text
In your letter dated January 15, 2025, on behalf of your client, Dr. Reddy’s Laboratories, Incorporated, you requested a tariff classification and country of origin determination ruling. Formoterol Soln Neb, imported in 20 mcg /2 mL vials, is a medicinal preparation containing Formoterol Fumarate Dihydrate, a long-acting beta agonists (LABAs), as the active ingredient. It is indicated for the treatment of bronchoconstriction in patients with Chronic Obstructive Pulmonary Disease (COPD).
The applicable subheading for the Formoterol Soln Neb (Formoterol Fumarate Inhalation Solution) in dosage form will be 3004.90.9289, Harmonized Tariff Schedule of the United States (HTSUS), which provides for “Medicaments … consisting of mixed or unmixed products for therapeutic or prophylactic uses, put up in measured doses … or in forms or packings for retail sale: Other: Other: Other: Medicaments primarily affecting the eyes, ears or respiratory system: Other: Other.” The rate of duty will be free.
Duty rates are provided for your convenience and are subject to change. The text of the most recent HTSUS and the accompanying duty rates are provided at https://hts.usitc.gov/. You also requested a country of origin determination. You stated that the active pharmaceutical ingredient (API), Formoterol Fumarate Dihydrate is manufactured in Italy and that the finished Formoterol Soln Neb (Formoterol Fumarate Inhalation Solution) in dosage form is made in India.
In India, Formoterol Fumarate Dihydrate will be mixed with inactive ingredients to produce the final Formoterol Fumarate Inhalation Solution in dosage form. Section 134.1(b), Customs Regulations (19 CFR 134.1(b)), defines "country of origin" as: The country of manufacture, production, or growth of any article of foreign origin entering the United States.
Further work or material added to an article in another country must effect a substantial transformation in order to render such other country the "country of origin" within the meaning of this part; … A substantial transformation occurs when an article emerges from a process with a new name, character or use different from that possessed by the article prior to processing. A substantial transformation will not result from a minor manufacturing or combining process that leaves the identity of the article intact.
See United States v. Gibson-Thomsen Co., 27 C.C.P.A. 267 (1940); and National Juice Products Association v. United States, 628 F. Supp. 978 (Ct. Int’l Trade 1986). In this case, we find the mixing of the active ingredient, Formoterol Fumarate Dihydrate (made in Italy) with the inactive ingredients into the final Formoterol Fumarate Inhalation Solution in dosage form in India does not result in a substantial transformation and the country of origin will be Italy.
This merchandise may be subject to the Federal Food, Drug, and Cosmetic Act and/or The Public Health Security and Bioterrorism Preparedness and Response Act of 2002 (The Bioterrorism Act), which are administered by the U.S. Food and Drug Administration (FDA).
The text above is an excerpt. The official ruling, with its letterhead, signature and any attachments, is on CBP CROSS (N345194).